In the United States, approximately one-fifth of breast cancers are diagnosed among women aged ≤50 years, totaling nearly 50,000 new cases of invasive breast cancer per year. 1 The percentage of incident cases among young women in Latin America, India, or sub-Saharan Africa is even greater, although whether this is due to differences in screening behavior, genetics, or lifestyle factors remains unclear.
INTRODUCTION
In the United States, approximately one-fifth of breast cancers are diagnosed among women aged ≤50 years, totaling nearly 50,000 new cases of invasive breast cancer per year. 1 The percentage of incident cases among young women in Latin America, India, or sub-Saharan Africa is even greater, although whether this is due to differences in screening behavior, genetics, or lifestyle factors remains unclear. 2 Breast cancer outcomes have been enhanced during the past decade due to improvements in early detection and treatment, with the largest decrease in breast cancer death rates noted among women aged 20 to 49 years. 3 However, this improved survival presents us with unique considerations. One such consideration is the impact of breast cancer therapy on ovarian function. For young patients with breast cancer, ovarian failure is a major long-term side effect of adjuvant treatment. Premature menopause as a result of ovarian failure, removal, or suppression is associated with attendant symptoms (eg, hot flashes, sweats, vaginal dryness, decreased libido, etc) that negatively impact health-related quality of life. 4 Premature menopause also increases long-term health risks (eg, bone health). In fact, in young women without breast cancer, premature ovarian failure/removal is reported to increase mortality, [5] [6] [7] although any such impact in patients with breast cancer would be difficult to discern given both the competing effects of cancer on mortality as well as the impact of ovarian suppression on reducing the rate of recurrence of hormone receptor-positive (HR+) breast cancer 8 and decreasing new breast cancer events. Younger patients also may desire to preserve fertility for childbearing. Because patients may be focused on prognosis at the time of the cancer diagnosis, clinicians must remain alert to the long-term consequences of treatment as breast cancer outcomes continue to improve. This is especially true when considering fertility, 9 which must be acted on early to mitigate such consequences, and pregnancy, 10 which necessitates careful individualized counseling. However, this counselling is limited by what to our knowledge is a relative lack of data regarding both outcomes either during or after breast cancer treatment. [11] [12] [13] Discussions with patients may be particularly hampered for "newer" agents such as trastuzumab 14, 15 and pertuzumab as well as for older agents such as platinums and capecitabine, which currently are receiving increased use in the (neo) adjuvant setting and for which less information regarding the impact on fertility or pregnancy may be available.
This issue of Cancer presents a report by Lambertini et al 16 regarding prospectively collected pregnancy information among patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who were enrolled on the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) 17 and Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) 18 randomized phase 3 trials. The authors compared pregnancy outcomes between patients who were unintentionally exposed to trastuzumab and/or lapatinib during gestation (exposed group) and those who became pregnant after the completion of trastuzumab and/or lapatinib treatment (unexposed group), as well as outcomes between those who became pregnant (pregnant cohort) and those who did not (not pregnant cohort) among women aged ≤40 years.
Pregnancy Outcomes During HER2-Targeted Therapy
Although the NeoALLTO 17 and ALLTO 18 studies required patients to use active contraceptive measures while receiving treatment, 12 patients unintentionally became pregnant during anti-HER2 therapy or shortly after treatment completion.
Cancer January 15, 2019 In these cases, short exposures to trastuzumab and/or lapatinib during gestation did not appear to affect newborn outcomes at the time of discontinuation of treatment, although as the authors noted, only a few live births (5 births) were described and only 3 births had exposure to HER2-targeted therapy (2 occurred in women without active exposure during gestation). There currently is an ongoing, prospective registry in women with breast cancer (the MotHER Pregnancy Registry) who have been or currently are being treated with a trastuzumab-containing regimen with or without pertuzumab or ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception that may produce valuable information to help in counseling future patients with breast cancer (ClinicalTrials.gov identifier NCT00833963).
It is worth reminding readers that "trastuzumab can cause fetal harm when administered to a pregnant woman, resulting in cases of oligohydramnios and pulmonary hypoplasia, skeletal abnormalities, and neonatal death" 19 and that to our knowledge there are no adequate and well-controlled studies to date regarding treatment with lapatinib in pregnant women. Thus, despite the reassuring findings of Lambertini et al, 16 women should be advised that anti-HER2-targeted treatment is not recommended during pregnancy, irrespective of the trimester. It is important to reinforce the need for the use of adequate contraception to young patients with breast cancer during and after an appropriate period after the completion of HER2-targeted therapy. If pregnancy is confirmed while receiving cancer treatment, the mother should be optimally managed by a multidisciplinary team to optimize maternal and fetal outcomes. 10 
Fertility and Pregnancy Outcomes After HER2-Targeted Therapy
As best as can be determined in the absence of randomized data, pregnancy after breast cancer does not increase the risk of disease recurrence, thereby reinforcing its safety irrespective of HR status. 20, 21 In the study by Lambertini et al, 16 among the 80 patients in the unexposed group, the first pregnancy occurred at a median of 48.6 months after the cessation of anti-HER2 therapy, with 54 patients (67.5%) successfully completing their pregnancy (median gestational week at the time of delivery was 39 weeks). No pregnancy or delivery complications were reported. Pregnancy after treatment completion in patients with HER2-positive early breast cancer appeared to be safe from both maternal and fetal perspectives.
A total of 1392 patients from the ALTTO trial who were aged ≤40 years at the time of diagnosis were included in the analysis investigating the prognostic effect of pregnancy after breast cancer. Among these patients, 85 conceived after study inclusion (pregnant cohort) and 1307 did not experience any pregnancy (not pregnant cohort). At a median follow-up of 6 years, no significant difference in disease-free survival was observed between the 2 cohorts. The study by Lambertini et al 16 provides reassurance regarding the safety and outcome of pregnancy after treatment of HER2-positive breast cancer, according to the authors. However, this is limited by a possible selection bias introduced by the patients or clinicians making the decision to forgo pregnancy based on concerns about an increased recurrence rate for those individuals at higher risk. Furthermore, the majority of pregnant patients were relatively far out from diagnosis, given when pregnancy occurred after diagnosis (median, 48.6 months; interquartile range, 25.1-70.1 months).
The mean age of women at the time of first childbirth has increased in recent decades, and was reported to be ≥30 years in the majority of countries within the Organisation for Economic Co-operation and Development, which comprises 36 countries. 22 Women diagnosed with breast cancer face additional limitations in becoming pregnant. They have the lowest chance of subsequent pregnancy (between 3%-7%) compared with other cancer survivors, and demonstrate pregnancy rates after a cancer diagnosis that are nearly 70% lower than those of the general population adjusted for age, previous parity, and educational level. 13 This may be related to chemotherapy-induced ovarian failure, prolonged treatment with endocrine agents, or risk-reducing salpingo-oophorectomy for those women with a BRCA mutation, as well as fear that pregnancy may stimulate cancer recurrence among patients with HR+ disease. Furthermore, recent data have demonstrated that adding ovarian function suppression to the treatment of patients with high-risk, early-stage HR+ breast cancer may lead to a further delay in pregnancy. 8 Temporary ovarian suppression during chemotherapy with gonadotropin-releasing hormone (GnRH) agonists such as goserelin or leuprolide has shown some promise as a way to decrease the incidence of chemotherapy-induced ovarian failure. 23 However, in their study, Lambertini et al 16 did not describe the use of GnRH agonists during experimental chemotherapy in the NeoALLTO and ALLTO studies, although adjuvant use was mentioned. Thus, we cannot make any additional conclusions regarding the impact of GnRH agonists in this setting. Likewise, details regarding these pregnancies did not include whether any fertility assistance was used: did any of these patients rely on methods of fertility Cancer January 15, 2019 preservation such as the use of oocytes or embryos that were harvested and frozen prior to embarking on breast cancer treatment?
Conclusions
The current study by Lambertini et al 16 adds to our understanding of pregnancy outcomes after HER2-targeted treatment of breast cancer. Ongoing efforts represent important attempts to advance the current knowledge. We can all further these efforts to understand pregnancy outcomes during and after cancer treatment by enrolling patients on studies such as MotHER (as mentioned above) as well as the Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE) trial (ClinicalTrials.gov identifier NCT0230805). POSITIVE is a prospective trial evaluating whether the interruption of adjuvant endocrine therapy to allow for pregnancy is associated with an increased risk of invasive breast cancer events. As we noted above, the best available evidence suggests that a pregnancy after a diagnosis of breast cancer does not increase the risk of disease recurrence. However, for women with HR+ disease who desire pregnancy after a diagnosis of breast cancer, the recommendation for 5 to 10 years of endocrine therapy poses special challenges if pregnancy is delayed to complete endocrine therapy; to the best of our knowledge, interrupted endocrine therapy has not been studied in a prospective manner. This important trial is open internationally and currently is accruing women aged 18 to 42 years with a diagnosis of early-stage, HR+ breast cancer. The primary endpoint is the breast cancer-free interval, with secondary endpoints including information regarding recovery and pattern of menses, pregnancy rates and outcomes, offspring outcomes, breastfeeding, use of assisted reproductive technologies, and the distant recurrence-free interval.
Efforts also should include supporting fertility and/or pregnancy correlatives on large adjuvant phase 3 breast cancer trials such as what occurred for the NeoALTTO 17 and ALTTO 18 randomized phase 3 trials, which enabled Lambertini et al 16 to produce their article. For example, EA1131: Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy (ClinicalTrials.gov identifier NCT02445391) is a randomized phase 3 trial examining outcomes for treatment with adjuvant capecitabine versus platinums in women with residual triple-negative breast cancer after neoadjuvant chemotherapy. EA1311 correlatives include assessing amenorrhea in the premenopausal population to determine the impact of these agents in women who have been previously exposed to anthracyclines and cyclophosphamide. Finally, we all can contribute to better real-world data collection outside of these studies by improving our cancer registries and discrete data collection with electronic health record systems. An enormous amount of work remains to address the pregnancy desires as well as pregnancy and disease outcomes of young women with early-stage breast cancer.
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